SOURCE: www.roboticoncology.com

www.roboticoncology.com

March 05, 2014 13:10 ET

Surgery Improves Prostate Cancer Survival Odds

Major European Study Names Prostate Surgery as Best First-Line Treatment for Localized Prostate Cancer, Says Leading Robotic Prostate Surgeon, David B. Samadi, MD

NEW YORK, NY--(Marketwired - Mar 5, 2014) - According to a large and highly regarded European study, men with localized prostate cancer who choose prostate removal surgery have a higher rate of survival than those who opt for radiotherapy. In a 15-year review of more than 34,000 Swedish men who underwent prostate cancer treatment, long-term mortality rates were significantly lower among surgery patients than radiotherapy patients.

While the highest survival rates were seen among younger patients with non-metastatic prostate cancer, even older men within the more advanced stages of the disease benefited from the surgery-first approach. David B. Samadi, MD, Chairman of Urology and Chief of Robotic Surgery at Lenox Hill Hospital, world-renowned prostate cancer expert and inventor of the Samadi Modified Advanced Robotic Technique (SMART) for prostate surgery, emphasized that the study results are consistent with his long held views on the benefits of prostate surgery. "When prostate cancer is diagnosed early, robotic surgery is the best way to optimize prostate cancer recovery and long-term survival."

Lead researchers are hopeful that the findings will help men and their families make more informed treatment decisions. The study also sheds light on the effectiveness of prostate surgery for patients in the early stages of cancer, just after diagnosis. Dr. Samadi has long encouraged men with localized prostate cancer to choose surgery first.

"If at any point in a man's future, we detect new prostate cancer cells, radiation gives us an effective Plan B after surgery," explains Dr. Samadi. "The reverse is rarely true. If radiotherapy is used first, the prostate and surrounding tissue are altered in such a way that surgery is rarely possible. These men are often left without a safety net."

By employing his robotic surgery expertise and custom SMART procedure, Dr. Samadi offers patients further surgical benefits. "We're optimizing the benefits of surgery through enhanced quality of life after prostate cancer," he said. "With proper adherence to post-surgery recommendations, 96 percent regain urinary control in two to three months and 85 percent enjoy sexual potency within 12-24 months."

Based on the Swedish population used in this study, nearly all cases reviewed were of Caucasian men. While the findings may not directly correlate to all ethnic populations, they are considered very strong based on the large sample size, the length of the review, and a 98 percent data collection completion rate. The study appears in the February 27th British Medical Journal, http://www.bmj.com/content/348/bmj.g1502.

Related Links:

http://www.roboticoncology-es.com/  

Google+: +DavidSamadi
Twitter: @drdavidsamadi
Facebook: facebook.com/drdavidsamadi

Contact Information

  • Contact Information
    David B. Samadi, M.D
    Chairman of Urology
    Chief of Robotic Surgery at Lenox Hill Hospital

    Tel: 1-212-365-5000
    Fax: 1-646-692-6744

    Address:
    485 Madison Avenue
    21st floor
    New York, NY 10022

    http://www.roboticoncology.com/contact/

    Google+: +DavidSamadi
    Twitter: @drdavidsamadi
    Facebook: facebook.com/drdavidsamadi